



## Supplementary Figure S1




Dermal reactions (DR) to A37 booster. DR were measured 48hr post inoculation. For a comparison, DR after the 6<sup>th</sup> vaccine reported in ref. 15, are given. Patient PR32 did not present for DR measurement.

## Supplementary Figure S2



Kynureine (A) and Tryptophan (B) concentrations in the plasma of AE37 vaccinated and boosted patients at the indicated time points are depicted. C and D show the percent change of individual kynureine and tryptophan values, respectively, at successive time-points compared to R0. Bars and circles represent medians and single individuals' values, respectively.

### Supplementary Figure S3



(A) Overall survival (OS) and (B) Metastasis free survival (MFS) are presented in months from first diagnosis. Metastatic patients at diagnosis were M1b. For non metastatic patients at diagnosis (B) the Gleason score refers to surgery evaluation. Dotted vertical lines define the sequential time points commonly used in prostate cancer for evaluating probability of survival/metastasis [18-21], such as 2 years (A), 3 years (A), 5 years (A and B), 7 years (B) and 10 years (A).